The global obesity epidemic has been bursting at the seams. However, a solution may be found in psychedelics such as psilocybin, which activates serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.” If this is the case, we may come one step closer to stopping the global obesity epidemic that could impact nearly half of all U.S. adults by 2030. At the moment, 34% of U.S. adults and up to 20% of children are considered obese. Those successful in helping to treat the epidemic could see multi-billion-dollar market opportunity. As we learn more about how useful such treatments can be, it’s opening a wide range of opportunity for companies like The Yield Growth Corp. (CSE:BOSS)(OTC:BOSQF), Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM), Mind Medicine Inc. (OTC:MMEDF), Johnson & Johnson (NYSE:JNJ), and Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF).
The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. announces that its majority owned subsidiary NeonMind, on June 3, 2020 filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin or psilocin (or analogs thereof) (“Psilocybin”) combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues.
The provisional patent is for a proposed guided psychedelic psilocybin therapy protocol using psychotherapy prior to, during and after the psychoactive effects of the Psilocybin are felt by the patient. The psychedelic assisted psychotherapy is designed to assist in gaining insights from positive psychedelic experiences, to be integrated into everyday life and to help plan, prepare and make sense of psychedelic experiences for a therapeutic result. It can include an exploration of unresolved issues in the patient’s life that are embedded in his or her subconscious, including discussions or examinations of pain. It may also include building self-esteem, the patient taking responsibility for his or her own condition, self empowerment, and acknowledging or releasing any unhealthy self defence mechanism of overeating.
NeonMind previously announced that it filed a provisional patent in December 2019 for the use of microdose administration of Psilocybin for weight loss benefits. NeonMind has retained contract research organization Translational Life Sciences Inc. to design and plan an initial preclinical study using psilocybin which is anticipated to begin in the fall of 2020. The preclinical study is anticipated to provide data to design phase 2 human clinical trials to test Psilocybin as a weight loss treatment. The phase 2 clinical trials are anticipated to begin in 2021, subject to receiving all required regulatory approvals.
NeonMind's combined provisional patent applications cover the administration of Psilocybin to provide weight loss benefits and potential treatment or regulation of diabetes, and regulation of blood glucose, and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus, hypertension, multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma, and certain forms of cancer.
The U.S. provisional patent application provides a right of priority under the Paris Convention as well as the Patent Cooperation Treaty (“PCT”). This means it establishes an effective filing date for inventions adequately described within it for PCT applications or applications in more than 170 countries who are members of the Paris Convention, as long as the foreign application is filed within one year of the provisional filing date.
Other related developments from around the markets include:
Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM) a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to sponsor TheraPsil, a BC-based non-profit coalition of healthcare professionals, policy-makers and community leaders seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress. Operating at highest standards of clinical competence and ethical integrity, the TheraPsil coalition is starting in 2020 with seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress.
Based in Victoria, British Columbia and established in 2019, TheraPsil is focused on Compassionate Access: Establishing safe, and legal access to psychedelic-assisted therapy for those in medical need; Public Education: Increasing awareness of the merits and limitations of psychedelic-assisted therapy; Professional Training; Developing safe, simple and effective protocols for credentialed health professionals to deliver psilocybin-assisted therapy, in collaboration with other active organizations; and, Research: Facilitate research and evaluation in collaboration with Canadian and international partners.
Mind Medicine Inc. (OTC:MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the leading neuro-pharmaceutical company for psychedelic inspired medicines and as part of its expanding slate of research and clinical trials, will add an additional clinical trial site and Principal Investigator at the University Hospital Basel in Basel, Switzerland, the birthplace of LSD for its Phase 2a clinical trial of LSD microdosing. MindMed’s microdosing division is pioneering the clinical development of consuming very low, sub-hallucinogenic doses of psychedelic substances. The company intends to continue building its microdosing division into a global leader for microdosing psychedelics and expand a diverse R&D pipeline of sub-hallucinogenic doses of psychedelics to treat various mental health issues.
Johnson & Johnson (NYSE:JNJ) announced that its Janssen Pharmaceutical Companies received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its investigational Ebola vaccine regimen for the prevention of the Ebola Virus Disease caused by the Zaire ebolavirus species. Two Marketing Authorisation Applications (MAAs) were submitted to the EMA in support of the vaccines in the two-dose regimen (Ad26.ZEBOV, MVA-BN-Filo). Janssen’s investigational Ebola vaccine regimen is specifically designed to support preventive vaccination in countries that are at risk of Ebola outbreaks, as well as for other at-risk groups such as healthcare workers, Biosafety Level 4 (BSL-4) lab workers, military deployed from other countries, airport staff and visitors to high-risk countries. Janssen is collaborating with the World Health Organization (WHO) on vaccine pre-qualification to broaden access of its investigational Ebola vaccine regimen to those most in need and enable registration in African countries; European Commission (EC) approval of this regimen may help accelerate this process.
Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has filed its Clinical Trial Application with Health Canada and provides an update on the filing of its Investigational New Drug package to the U.S. Food and Drug Administration for the proposed Phase 3 confirmatory clinical trial to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection. “We are very pleased with the progress that has been made with our clinical strategy for Bucillamine in the potential treatment of COVID-19, specifically with our focus on a Phase 3 confirmatory study to be conducted in the U.S. and our expansion into Canada,” said Michael Frank, Revive’s Chief Executive Officer. The Company will have its Pre-CTA meeting with Health Canada this week. A complete briefing package accompanied the meeting request to discuss Bucillamine’s Chemistry, Manufacturing and Controls, non-clinical and clinical safety information, clinical trial design, and Health Canada’s guidance regarding the possibility of including an additional exploratory arm in the proposed trial in a subset of patients from the pediatric population. Results from the Pre-CTA meeting with Health Canada will be made available and the Company expects to initiate a clinical study as soon as possible following receipt of regulatory clearance from Health Canada.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of www.MarijuanaStox.com) and The Yield Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.
Contact Information:
2818047972
[email protected]
